ROG - Rapt Therapeutics Seeks $75 Million In U.S. IPO
Quick Take
Rapt Therapeutics (RAPT) has filed to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is focused on developing small-molecule drugs for patients with high unmet clinical needs in oncological and inflammatory diseases.
RAPT is preparing to enter Phase 2 trials so the IPO may be more appropriate for long-term investors with a multi-year hold timeline.
Company & Technology
San Francisco, California-based Rapt Therapeutics was founded in 2005 to develop immunology-based small-molecule drugs [SMDs] for oncological and inflammatory diseases.
Management is